Milestone Scientific (NYSE:MLSS) said this week that it appointed Daniel Goldberger to the company’s corner office. Leonard Osser, who previously served as CEO, is slated to remain on the board and will continue to serve as director of Milestone’s China operations.
The appointment comes on the heels of the FDA’s decision to grant Milestone’s CompuFlo epidural computer-controlled anesthesia system 510(k) clearance.
As CEO, Goldberger is tasked with transitioning Milestone to a commercial company as it launches the CompuFlo system for the first time.
Goldberger has held leadership positions at an array of medical technology companies, including Xtant Medical Holdings and Sound Surgical Technologies.
“I am thrilled to accept this position at such an important inflection point as Milestone transitions from an R&D focused organization to a commercially focused medical device company,” Goldberger said in prepared remarks. “Milestone’s painless and precise computerized injection technology platform has the potential to transform drug delivery. Over the coming years, we will be laser focused on sales and marketing activities, including building our global distribution network. Since receiving marketing clearance for the first instruments in Europe, Milestone has been successful in attracting key opinion leaders. Following our recent FDA marketing clearance of the epidural instrument, I look forward to now converting the growing enthusiasm among medical practitioners into broad global commercial adoption.”
“We are pleased to announce the appointment of Daniel Goldberger as chief executive officer,” Osser added. “He brings a proven track record driving sales and global market adoption of medical devices to Milestone. Dan’s skill sets will be invaluable as we enter the next phase of our growth, in which we will be heavily focused on the commercial rollout of our epidural instrument. As a member of the Board of Directors, Director of China Operations and a significant stockholder, I look forward to overseeing our continued expansion in China and supporting Dan in his leadership role.”
“Since returning as CEO, Leonard Osser has executed on a focused vision to bring our technology to the medical industry,” chairman Leslie Bernhard said. “This vision has now been realized with the recent FDA clearance of our epidural instrument, as well as European marketing clearance of both the epidural and intra-articular instruments. Dan Goldberger had been tapped by Leonard and the board to lead Milestone into its next stage of commercial growth and development. We look forward to establishing Milestone’s platform technology as the standard-of-care in painless and precise drug delivery in the U.S., Europe and around the world.”
“Wendy is a proven leader with deep industry knowledge in forging strategic partnerships and a track record of getting things done and delivering results,” CEO Patrick Anquetil said in prepared remarks. “Wendy will lead our business development efforts, focusing on advancing the eventual commercialization of our platform.”
Previously, Dwyer served as VP of corporate development at Ipsen BioScience. She has also worked in business development at AztraZeneca.
“I am excited about the road ahead for Portal, recognizing the important and valuable achievements in this unique drug delivery platform and the opportunities to forge strategic industry partnerships to improve the patient experience,” Dwyer said. “I am delighted to join such a committed and motivated team and look forward to helping in the continued growth of Portal.”
Foamix Pharmaceuticals promotes Domzalski to CEO
Foamix Pharmaceuticals (NSDQ:FOMX) said last month that it promoted David Domzalski, who used to lead the company’s U.S. subsidiary, to CEO. Domzalski took the place of Dov Tamarkin, who transitioned to chief scientific advisor.
The company also announced that Meir Eini will step down from his role as chief innovation officer and will serve as an innovation advisor.
“On behalf of the entire board of directors, I want to thank Dov Tamarkin for his dedicated leadership and contributions to Foamix. Along with Co-founder Meir Eini, Dov has built Foamix from a small privately held company in Israel into a fully integrated publicly traded specialty pharmaceutical company with an innovative proprietary technology platform and two advanced clinical development programs currently in Phase III,” chairman Stanley Hirsch said in prepared remarks. “Dov, Meir and the board have determined that it is the right time to transition to new leadership as the company focuses on completing the Phase 3 programs for FMX101 and FMX103, expanding the pipeline, and preparing the organization for its next phase of growth. We are confident that Dave will successfully lead Foamix in these efforts, generating better outcomes for patients and creating value for Foamix’s shareholders.”
“I am very excited to lead Foamix at this important time and, together with our strong senior management team, will continue to work diligently to advance our lead programs, with the goal of bringing new innovative solutions to patients,” Domzalski added. “I look forward to working with our leadership team and the board to strengthen Foamix for long-term sustained growth.”
“We are delighted to welcome Dr. Simantov to Gamida Cell. We are now enrolling patients to the Phase III registration study of our FDA breakthrough designation product, NiCord. Dr. Simantov will play a central role in the late stage development program and associated activities geared towards commercialization of NiCord, backed by the recently announced $40 million financing,” president & CEO Yael Margolin said in prepared remarks.
Simantov previously worked as VP and head of global medical affairs at Pfizer Oncology.
“Gamida Cell has an innovative pipeline of cellular and immune therapies with the potential to address significant patient needs in cancer and hematologic disease,” Simantov said. “I look forward to leading the clinical development and regulatory path to approval of NiCord, a novel graft modality for patients undergoing bone marrow transplantation.”
“Savvy stewardship of capital will be a major factor in the continued advancement of our ambitiously paced clinical pathway,” chairman & CEO Shane Schaffer said in prepared remarks. “We believe the appointment of an experienced chief financial officer is paramount to successful execution of our development programs, and we are pleased to have attracted a leader of Lou’s caliber for this critical role on our executive team.”
“I’m excited to join Cingulate at this pivotal time in the company’s growth,” Van Horn added. “As we prepare our two lead drugs for pivotal clinical trials, I look forward to leveraging my finance experience to support the development efforts and advance these innovative ADHD therapeutics as efficiently as possible toward potential FDA approval and commercialization.”
Previously, Van Horn served as exec VP and CFO with Store Financial Services.
- Mannkind brings on new chief commercial exec
- Biogen names Steele as senior VP of corporate affairs
- Avalon appoints chief growth officer, COO
- Novaliq hires new chief medical exec
- Biogen appoints VP of government affairs